Gubra A S

Good morning, everyone, and welcome to GroupBus conference call covering our first half 2026 results. My name is Adam, new head of investor relations at GroupBus.

And joining me today are members of GroupBus leadership team who will take the pool Key developments for the company in the first six months of 2026 and our financial results. Following the presentation, we will open the call for questions. Before we begin, I will just caution listeners on slide two here that we may make forward looming statements that are subject to risks and uncertainties. And with that, I will hand over the call to our CEO, Markus, for opening remarks.

Thank you very much, Adam. Good morning, everyone. Welcome also from my side to our webcast. I'd like to give a couple of highlights of the company. In summary, I believe Gruber had a very good first half of the year across our entire business units. Gruber Biotech significantly advanced our R&D pipeline. and in the CEO, I think while we still have work to do, I see a promising trend based on new commercial initiatives and also continued cross-discipline. And we have also now established a platform for Gruber Ventures. This is a new business unit at Gruber and we are currently evaluating multiple deals and over the next couple of months, I hope we can announce the first Gruber Venture. At this point, I'd like to remind you that our business model is unique. Based on three synergistic business units, Gruber Biotech discovers and develops new peptide therapeutics up to Clinically Proof of Concept, Gupa Ventures invests in exciting science adjacent to our flagship areas, and our COO, while serving many external customers, is an integral and very important part of our innovation in the biotech unit as well in our new ventures. Let me highlight a couple of milestones which already have been achieved. In the first half of the year, I'm just going to mention three of them. UPI reported highly encouraging phase one MAD results for the long-acting amylin. I think this is very robust data, and the start of the phase two is imminent. Bernie Inheim has already advanced the triple agonist in clinical phase two, and we now have initiated and ambitious phase one to a trial for our fully owned UCN2 program, our new mega program. And with this, I'd like to hand over to Louise.